Hydroxychloroquine in Untreated B-CLL Patients

Summary

Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine 400mg po daily for up to one year. They will be monitored for disease status as well as adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required at baseline and every 6 months or sooner if the patient develops any visual disturbances.

Timeline

Start

2008-07

Primary completion

2012-01

Completion

2012-01

Outcome

Outcome not reported

Stopped: “study suspended while data is reviewed for safety and efficacy.”

Drugs

Indications